Oxaloacetate CFS Earning Widespread Attention From ME/CFS Research Community

After its launch in 2023, Oxaloacetate CFS immediately gained the attention of the ME/CFS research community. Research collaborations with Stanford University, Mount Sinai Health System, The Bateman Horne Center, University of California Los Angeles, University of Melbourne Australia, University of Michigan and many more have already yielded multiple peer-reviewed studies including three separate double-blind, peer-reviewed clinical trials involving ME/CFS and Long COVID patients.

The results of these studies have been featured by leading voices in the ME/CFS research community at the ME/CFS Research Foundation International Conference in Berlin and multiple conferences by The International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME).

Dr. Susan Vernon Discusses Clinical Data of Oxaloacetate CFS Showing Fatigue and Cognitive Function Improvements in ME/CFS and Long COVID patients

Alan Cash Presents Oxaloacetate CFS Data To International ME/CFS Conference, Berlin

Dr. Kaufman Explains Research and Practice of Using Oxaloacetate CFS as Medical Food for ME/CFS